SEARCH

SEARCH BY CITATION

References

  • 1
    Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med 2004; 350: 11181129.
  • 2
    Lee WM. Hepatitis B virus infection. Med Prog 1997; 337: 17331745.
  • 3
    Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. HEPATOLOGY 2006; 43: 209220.
  • 4
    Xunrong L, Yan AW, Liang R, Lau GKK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy—pathogenesis and management. Rev Med Virol 2001; 11: 287299.
  • 5
    Liang R, Lau GKK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999; 17: 394398.
  • 6
    DeVita VT, Hubbard SM, Longo DL. The chemotherapy of lymphomas: looking back, moving forward—the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 1987; 47: 58105824.
  • 7
    Koak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990; 8: 963977.
  • 8
    Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 6168.
  • 9
    Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88: 84958499.
  • 10
    Ahmed A, Keeffe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 1999; 94: 249251.
    Direct Link:
  • 11
    Yeo W, Chan PKS, Chan HLY, Mo FKF, Johnson PJ. Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol 2001; 65: 473477.
  • 12
    Li YH, He YF, Jiang WQ, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006; 106: 13201325.
  • 13
    Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004; 83: 270275.
  • 14
    Idilman R, Arat M, Soydan E, Toruner M, Soykan I, Akbulut H, et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 2004; 11: 141147.
  • 15
    Lau GKK, Yiu HHY, Fong DYT, Cheng HC, Au WY, Lai LSF, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 17421749.
  • 16
    Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 100: 391396.
  • 17
    Lee GW, Ryu MH, Lee JL, Oh S, Kim E, Lee JH, et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci 2003; 18: 849854.
  • 18
    Lok AS, McMahon BJ. AASLD Practice Guidelines: chronic hepatitis B. HEPATOLOGY 2001; 34: 12251241.
  • 19
    Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001; 115: 5862.
  • 20
    Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2002; 116: 166169.
  • 21
    Faggioli P, Paschale MD, Tocci A, Luoni M, Fava S, De Paoli A, et al. Acute hepatic toxicity during cyclic chemotherapy in non-Hodgkin's lymphoma. Haematologica 1997; 82: 3842.
  • 22
    Yeo W, Chan PKS, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299307.
  • 23
    Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B, et al. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. Haematologica 2003; 88: 12961303.
  • 24
    Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999; 46: 29252930.
  • 25
    Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182188.
  • 26
    Persico M, De Marino F, Russo GDG, Morante A, Rotoli B, Torella R, et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin's lymphoma. Blood 2002; 99: 724725.
  • 27
    Fouillard L, Serfaty L, Gozlan J. Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 37: 625626.
  • 28
    Cortelezzi A, Vigano M, Zilioli VR, Fantini NN, Pasquini MC, Deliliers GL, et al. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with campath-1H. J Clin Virol 2006; 35: 467469.
  • 29
    Enomoto M, Nishiguchi S, Seki S, Yamane T, Hino M. Adefovir dipoxil to prevent exacerbation of lamivudine-resistant hepatitis B infection during chemotherapy for non-Hodgkin's lymphoma. Am J Gastroenterol 2004; 99: 16191620.
    Direct Link:
  • 30
    Lok AS, McMahon BJ. AASLD Practice Guidelines: chronic hepatitis B: update of recommendations. HEPATOLOGY 2004; 39: 857861.
  • 31
    Gauthier J, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999; 180: 17571762.
  • 32
    Hui CK, Cheung WWW, Au WY, Lie AK, Zhang HY, Yueng YH, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancies on completion of cytotoxic chemotherapy. Gut 2005; 54: 15971603.
  • 33
    Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004; 83: 769774.
  • 34
    PDR Staff. Red Book. 110th ed. Thomson Healthcare (Montvale, NJ); 2006.
  • 35
    Hoover D, Crystal S, Kumar R. Medical expenditures during the last year of medical expenditures during the last year of life: findings from the 1992-1996 Medicare current beneficiary survey. Health Serv Res 2002; 37: 16251642.
  • 36
    U.S. Department of Labor Bureau of Labor Statistics. Consumer price index calculator. Available at: http://www.bls.gov. Accessed May 2007.
  • 37
    Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. JAMA 1996; 276: 11721177.
  • 38
    Petitti D. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. New York, NY: Oxford University Press; 2000.
  • 39
    Webster A, Brenner MK, Prentice HG, Griffiths PD. Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant 1989; 4: 207208.
  • 40
    Mertens T, Kock J, Hampl W, Schlicht HJ, Tillmann HL, Oldhafer KJ, et al. Reactivated fulminant hepatitis B virus replication after bone marrow transplantation: clinical course and possible treatment with ganciclovir. J Hepatol 1996; 25: 968971.
  • 41
    Yoshiba M, Sekiyama K, Sugata F, Okamoto H, Yamamoto K, Yotsumoto S. Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment. Dig Dis Sci 1992; 37: 12531259.
  • 42
    Peters MG, Hann HW, Martin P, Tillinger W, Reinisch W, Fueger GF, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91101.
  • 43
    Perillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 8190.
  • 44
    Gerolami R, Bourliere M, Colson P, Halfon P, Borentain P, Henry M, et al. Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases. Antivir Ther 2006; 11: 11031106.
  • 45
    Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE IV. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10: 625633.
  • 46
    Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004; 15: 16611666.
  • 47
    Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 2004; 24: 540546.
  • 48
    Yeo W, Hui EP, Chan ATC, Ho WM, Lam KC, Chan PK, et al. Prevention of hepatitis B Reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 2005; 28: 379384.
  • 49
    Tsai FC, Hseih HC, Chen DS, Shen JC, Chen DS. Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents. Dig Dis Sci 2006; 51: 16271632.
  • 50
    Murakami R, Amada N, Sato T, Orii T, Kikuchi H, Haga I, et al. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single center experience. Clin Transplant 2006; 20: 351358.
  • 51
    Shitrit AB-G, Kramer MR, Bakal I, Morali G, Ari ZB, Shitrit D. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation. Ann Thorac Surg 2006; 81: 18511852.
  • 52
    Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Fome M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 13631365.
  • 53
    World Health Organization. Hepatitis B. Available at: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index1.html. Accessed May 2007.